Global Acellular Pertussis-based Hexavalent Combination Vaccine Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Acellular Pertussis-based Hexavalent Combination Vaccine market size was valued at US$ 2419 million in 2025 and is forecast to a readjusted size of US$ 3518 million by 2032 with a CAGR of 5.5% during review period.
An acellular pertussis-based hexavalent combination vaccine is a multivalent pediatric vaccine designed primarily for the primary immunization and, depending on national recommendations and product authorization, booster immunization of infants and young children. It is commonly designated as DTaP-IPV-HepB-Hib and combines diphtheria toxoid, tetanus toxoid, purified acellular pertussis antigens, inactivated poliovirus antigens, recombinant hepatitis B surface antigen, and a conjugated Haemophilus influenzae type b antigen. It therefore provides protection against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, and invasive diseases caused by Hib. Compared with schedules using several monovalent or lower-valency vaccines, a hexavalent vaccine can reduce the number of injections, clinic visits and administration procedures, improving the convenience and operational efficiency of pediatric immunization. It is a technologically complex biological product rather than a simple antigen mixture, requiring multiple fermentation, cell-culture, recombinant-expression, purification, detoxification, conjugation, adsorption and formulation platforms, together with rigorous control of antigen compatibility, potency and manufacturing consistency.In 2025, global Acellular Pertussis-based Hexavalent Combination Vaccine production reached approximately 29 million units.The average gross profit margin of this product is 85%.
The principal market opportunity is the continuing transition of pediatric immunization programs from fragmented, injection-intensive schedules toward simplified combination-vaccine schedules. Hexavalent products can preserve broad disease protection while reducing injections, appointment requirements and vaccine-handling procedures, potentially lowering the risk of delayed, missed or incomplete vaccination. The renewed circulation of pertussis in a number of regions has also reinforced the importance of timely completion of infant pertussis immunization. In established markets, demand is supported by the continued optimization of national childhood vaccination schedules and replacement of older combination products. In emerging economies, a larger long-term opportunity may arise as immunization systems move from pentavalent vaccines combined with separately administered hepatitis B or inactivated polio vaccines toward integrated hexavalent formulations. These trends favor companies with established antigen platforms, internationally compliant manufacturing capacity, dependable supply and experience in multinational registration and public-sector procurement.
The principal barriers arise from scientific, manufacturing and regulatory complexity rather than an absence of medical need. Six antigen components must deliver appropriate immune responses and acceptable safety profiles within a common formulation or vaccination system, while avoiding clinically meaningful interference between components. Variability in one antigen, an interruption in a critical raw material or a delay in batch release can affect the availability of the entire vaccine. Manufacturers must also conduct extensive clinical evaluations covering primary schedules, booster use, interchangeability and co-administration with other pediatric vaccines, followed by continuous pharmacovigilance. Commercialization is further complicated by differences in national immunization schedules, tendering systems, reimbursement policies, local supply requirements and price negotiations. Waning pertussis immunity, changes in birth cohorts, vaccine hesitancy and fluctuations in government immunization budgets may also influence demand. Established products benefit from extensive clinical experience and physician confidence, creating a substantial time and credibility barrier for new entrants.
Downstream purchasing criteria are expanding beyond disease coverage to include schedule efficiency, completion rates, supply reliability and value across the entire vaccination pathway. National immunization programs and public procurement agencies increasingly evaluate whether a vaccine can simplify delivery, reduce operational complexity at primary-care facilities and maintain dependable long-term supply. Private hospitals, pediatric clinics and self-pay vaccination markets place greater emphasis on fewer injections, convenient presentations, established safety records and parental acceptance. Digital immunization registries, appointment reminders and integrated child-health management systems are also improving the visibility of missed doses and supporting more standardized vaccination pathways, which strengthens the clinical value of combination vaccines. Future market expansion is therefore expected to be driven primarily by structural substitution for fragmented vaccination schedules rather than birth-cohort growth alone. Products capable of supporting both primary and booster strategies, adapting to different national schedules and demonstrating consistent real-world safety performance will be better positioned in downstream markets.
This report is a detailed and comprehensive analysis for global Acellular Pertussis-based Hexavalent Combination Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Acellular Pertussis-based Hexavalent Combination Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Acellular Pertussis-based Hexavalent Combination Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Acellular Pertussis-based Hexavalent Combination Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Dose), and average selling prices (US$/Dose), 2021-2032
Global Acellular Pertussis-based Hexavalent Combination Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Dose), and ASP (US$/Dose), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Acellular Pertussis-based Hexavalent Combination Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Acellular Pertussis-based Hexavalent Combination Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, Sanofi, MSP Vaccine Company, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Acellular Pertussis-based Hexavalent Combination Vaccine market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Prefilled
Vial
Market segment by Application
Public
Private
Major players covered
GSK
Sanofi
MSP Vaccine Company
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Acellular Pertussis-based Hexavalent Combination Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Acellular Pertussis-based Hexavalent Combination Vaccine, with price, sales quantity, revenue, and global market share of Acellular Pertussis-based Hexavalent Combination Vaccine from 2021 to 2026.
Chapter 3, the Acellular Pertussis-based Hexavalent Combination Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Acellular Pertussis-based Hexavalent Combination Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Acellular Pertussis-based Hexavalent Combination Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Acellular Pertussis-based Hexavalent Combination Vaccine.
Chapter 14 and 15, to describe Acellular Pertussis-based Hexavalent Combination Vaccine sales channel, distributors, customers, research findings and conclusion.